Cipla Limited

Equities

CIPLA

INE059A01026

Pharmaceuticals

Market Closed - NSE India S.E. 06:43:35 2024-02-23 am EST 5-day change 1st Jan Change
1,466 INR +0.90% Intraday chart for Cipla Limited +1.78% +17.66%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
India pharma companies develop versions of Wegovy to get in on weight-loss windfall RE
Indian Equities Close Higher Midweek, Led by Banking, IT Stocks MT
Indian drugmaker Lupin beats quarterly profit estimates on strong demand RE
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand RE
India's Alembic Pharma beats Q3 profit view on strong domestic, US sales RE
Cipla Eyes Acquisitions and Inorganic Partnerships in the US, European markets CI
India's Jubilant Pharmova posts quarterly profit RE
India's Torrent Pharma posts higher Q3 profit on strong domestic demand RE
Loss in Bank Stocks Drags Indian Equities to End Lower on Thursday MT
Indian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businesses RE
Nomura Downgrades Cipla to Neutral From Buy, Price Target to INR1,427 From INR1,353 MT
Indian Equities End Strongly on Monday Ahead of Interim Budget, US Rate Decision MT
Jefferies Adjusts Cipla’s Price Target to INR1,250 From INR1,210, Keeps at Hold MT
Selling in IT, Banking Stocks Drag Indian Equities on Thursday MT
Transcript : Cipla Limited, Q3 2024 Earnings Call, Jan 25, 2024
Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson CI
Cipla Seeks Inorganic Growth CI
Cipla Forms New Mexican Subsidiary MT
Indian Equities Sink on Tuesday Amid Waning Hopes for US Rate Cuts MT
INDIA STOCKS -Indian shares slump 1.5% as financials weigh; Zee plunges RE
Cipla's Consolidated Profit Jumps in Fiscal Q3; EPS, Revenue Top Estimates MT
Cipla Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Indian Equities Extend Losses to Third Day Amid Rising US Bond Yields MT
Indian Equities Close Higher on Friday, Lifted by IT Stocks MT
Indian Equities Close Higher on Wednesday, Lifted by IT, Metal Stocks MT
Chart Cipla Limited
More charts
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
1,466 INR
Average target price
1,428 INR
Spread / Average Target
-2.64%
Consensus
  1. Stock
  2. Equities
  3. Stock Cipla Limited - NSE India S.E.
  4. News Cipla Limited
  5. Cipla's Arm Acquires Additional 15% Stake in Joint Venture
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer